Briefs: FDA approves Abbott HIV drug

LIBERTYVILLE TOWNSHIP -- Abbott Laboratories announced that it received U.S. Food and Drug Administration approval for a new lower-strength tablet formulation of its leading HIV protease inhibitor, Kaletra. The lower-strength Kaletra tablets will be available in the U.S. this month and will be an advancement in delivering HIV medicine to children, the firm said.

CoreSource unveils health-care service

LAKE FOREST -- CoreSource has introduced an integrated suite of total population management solutions called CoreCare to the self-funded health-care marketplace. The new services are designed to minimize an employer's medical plan costs by improving prevention, identification and management of health-care risks within their employee ranks.